Stoke Therapeutics

Stoke Therapeutics is addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.

[Stoke Therapeutics @StokeTx]

Stoke has entered into a collaboration with @biogen to develop and commercialize our lead therapeutic candidate for the treatment of #Dravetsyndrome. Learn more: https://t.co/QS43MER2Im

[Stoke Therapeutics @StokeTx]

Stoke was proud to participate in the Rare Advocate Development (RAD) Brain Workshop in NYC this week. Thank you to the organizers, @RareEpilepsy, @GlobalGenes, and Mahzi Therapeutics for empowering patient advocates to advance therapeutic options.

[Stoke Therapeutics @StokeTx]

Don’t miss CEO Dr. Edward Kaye take the stage at #JPM2025. Tune in to learn more about our entry to late-stage development in Dravet syndrome and future potential for the company's platform to address additional diseases of the CNS and the eye. https://t.co/AaBre6GS5Q

[Stoke Therapeutics @StokeTx]

Stoke Therapeutics CEO, Dr. Edward Kaye, is scheduled to present at #JPM2025 on Wednesday, January 15.

Save the date to join the live audio webcast or access the replay afterward: https://t.co/AaBre6GS5Q

#Biotech #Healthcare #JPM25

[Stoke Therapeutics @StokeTx]

Stoke has achieved alignment with global regulators for the first-ever Phase 3 study of a potential disease-modifying medicine for Dravet syndrome.

This offers a promising opportunity to change how the disease is treated.

Learn more: https://t.co/3KEfIlRG4a

[Stoke Therapeutics @StokeTx]

This holiday season, we’re reflecting on the resilience and strength of the patients and families who inspire us every day. To our team, partners, and community—thanks for your support and dedication.

From us at Stoke, happy holidays and best wishes for a bright new year!

[Stoke Therapeutics @StokeTx]

@Rglock17 Thank you for your interest! The recording can be found on the Events and Presentations page of our website: https://t.co/8EY4rJdCh4.

[Stoke Therapeutics @StokeTx]

Save the date for our Investor & Analyst Virtual Educational Event, tomorrow 12/9, to explore #DravetSyndrome, current treatments, and the potential of disease-modifying medicines.

Register now to hear from leading clinicians & patient advocates: https://t.co/IXc9wbSHRB

[Stoke Therapeutics @StokeTx]

Today, our investigational new medicine for #DravetSyndrome received @US_FDA Breakthrough Therapy designation.

With no approved therapies, this designation highlights the urgent need for new solutions and brings hope to patients with Dravet.

Learn more: https://t.co/yHfFLe9rQa

[Stoke Therapeutics @StokeTx]

We’re presenting new clinical data from our Dravet syndrome program at #AES2024.

These updates highlight progress in reducing seizures and improving cognition and behavior.

Learn more: https://t.co/WO1SOF5lOe

[Stoke Therapeutics @StokeTx]

This Thanksgiving, we're grateful for the dedication, teamwork, and shared vision that drive us forward every day. Our team's commitment to making a difference for patients and families continues to inspire us.

#HappyThanksgiving from all of us at Stoke, to you and yours!

[Stoke Therapeutics @StokeTx]

Today on Autosomal Dominant Optic Atrophy (ADOA) Awareness Day, Stoke is standing alongside individuals and families affected by #ADOA. This condition brings unique challenges to those who live with it. We applaud the ADOA Association and @CureADOA for their ongoing advocacy.

[Stoke Therapeutics @StokeTx]

Stoke Therapeutics management will present at the @Jefferies London Healthcare Conference today at 6:30am EST (11:30am GMT). A live webcast of the presentation by our CEO, Dr. Edward Kaye, will be available on our website: https://t.co/Ttgi84aYis

#JefferiesHealthcare

[Stoke Therapeutics @StokeTx]

It’s Epilepsy Awareness Day at Disneyland! Stoke is proud to attend this year’s event and are grateful for the organizers for all their efforts in raising awareness and sharing knowledge.

#ThePurplestPlaceOnEarth #EpilepsyAwarenessDayAtDisneyland

[Stoke Therapeutics @StokeTx]

Living with #DravetSyndrome takes resilience. Not only from patients but also from the caregivers who support them every day.

This #FamilyCaregiversMonth, we honor these strong caregivers.

For tools and resources visit @curedravet: https://t.co/7m9UAcVndj

[Stoke Therapeutics @StokeTx]

Today on #SUDEPActionDay2024, we’re raising awareness about Sudden Unexpected Death in Epilepsy (#SUDEP) and the importance of understanding its risks. By supporting ongoing research, we can help improve safety for those affected.

Learn more: https://t.co/9lcNFi4JfZ

[SUDEP Action @SudepAction]

Today is #SUDEPActionDay2024 & we are uniting with organisations around the world to raise awareness of the rights of people with epilepsy or those bereaved by it. The epilepsy community is entitled to have their questions answered and the right to information, medication & care.

[Stoke Therapeutics @StokeTx]

Today, Stoke announced highlights from presentations at the 15th European Epilepsy Congress related to the Company’s work to develop the first disease-modifying medicine for #Dravetsyndrome.

https://t.co/U9vrpTRyYG

#ILAE #EEC2024 @IlaeWeb

[Stoke Therapeutics @StokeTx]

Stoke is pleased to announce the appointment of Eric Olson as Chief Business Officer.

Mr. Olson brings two decades of successful corporate business development experience with an emphasis on #rarediseases and #RNA therapeutics

https://t.co/fIbQEf1bL1

[Stoke Therapeutics @StokeTx]

Today we announced upcoming investor conference presentations at @HCWCO’s 26th Annual Global Investment Conference and @cantorfitzgerld’s 2024 Global Healthcare Conference.

Learn more: https://t.co/MGBcbxG3Tz

#CantorHCC #Biotech #innovation #investment

[Stoke Therapeutics @StokeTx]

The Stoke team is heading to @IlaeWeb’s 15th European #Epilepsy Congress in Rome!

We look forward to sharing encore data from our #Dravetsyndrome clinical program.

Learn more about our upcoming presentations: https://t.co/LopQhWgxhT

#EEC2024 #ILAE